Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 7/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22735720 | 1.00 | EGLN1 (0.36) | EGLN1RETMCL1JAK2KCNJ1 | |
| SCHEMBL29480471 | 0.84 | EGLN1 (0.37) | EGLN1JAK2GRM4JAK1JAK3 | |
| SCHEMBL22735993 | 0.84 | EGLN1 (0.37) | EGLN1JAK2GRM4JAK1JAK3 | |
| Hydrochloric Acid SCHEMBL29480556 | 0.83 | EGLN1 (0.36) | EGLN1JAK2GRM4JAK1JAK3 | |
| SCHEMBL29480555 | 0.81 | GRM4 (0.38) | EGLN1JAK2GRM4 | |
| SCHEMBL22736280 | 0.81 | GRM4 (0.38) | EGLN1JAK2GRM4 | |
| SCHEMBL22736023 | 0.81 | JAK2 (0.35) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL22716885 | 0.80 | GCG (0.39) | EGLN1JAK2JAK3 | |
| SCHEMBL29567469 | 0.80 | GCG (0.39) | EGLN1JAK2JAK3 | |
| SCHEMBL22716880 | 0.80 | JAK2 (0.40) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | claimed |
| US-12516056-B2 | Compounds for inhibition of janus kinase 1 | MANKIND PHARMA LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | disclosed |
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | EGLN1 1048/4885RET 440/4885MCL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.